Cemiplimab (Libtayo) is a human monoclonal antibody injected intravenously that targets programmed cell death-1 receptor (PD-1) and blocks its interaction with programmed death ligands PD-1 and PD-L2. Source: HEK293
In vivo: Cemiplimab (REGN2810) binds to the humanized PD-1 receptor and inhibits tumor growth in MC38 mice in human PD-1 knockout mice. REGN2810 has a high affinity for cynomolgus monkey PD-1, and its pharmacokinetics and toxicology were studied in cynomolgus monkey. High dose REGN2810 was well tolerated without adverse immune-related effects. In vitro: In cell-based assays, REGN2810 reversed PD-1-dependent attenuation of T-cell receptor signaling and enhanced human primary T-cell responses.
|Storage||4°C , protect from light , dry , sealed|
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
 Krishnansu S Tewari, et al. N Engl J Med. Survival with Cemiplimab in Recurrent Cervical Cancer
 Alexander J Stratigos, et al. Lancet Oncol. Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial
 Ahmet Sezer, et al. Lancet. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial
 Arnold Lee, et al. Drugs. Cemiplimab: A Review in Advanced Cutaneous Squamous Cell Carcinoma
 Michael R Migden, et al. N Engl J Med. PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma
|Related PD-1/PD-L1 Products|
|Human PD-L1 inhibitor V
Human PD-L1 inhibitor V is a human PD-1 protein binding peptide with a Kd value of 3.32 μM that inhibits the binding of human PD-1/PD-L1.Sequence:Leu-Asp-Tyr-Val-Asn-Arg-Arg-Lys-Met-Tyr-Gln.
ARB-272572 is a potent small molecule PD-L1 inhibitor with an IC50 value of 400 pM.
AUNP-12, a new immune checkpoint modulator, is an inhibitor of the PD-1 pathway.
CA-170 is an orally delivered dual inhibitor of VISTA and PD-L1.
Evixapodlin (PD-1/ PD-L1-in 7) is an inhibitor of human PD-1/PD-L1 protein/protein interaction with an IC50 of 0.213 nM. Evixapodlin has anti-cancer and anti-virus properties.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.